Idiopathic Pulmonary Fibrosis - Applying New Options to Real World Cases



The cost for this online activity is $15. This presentation was recorded LIVE on February 4, 2016 and is approximately 50 minutes. 

You must login or create an account before enrolling in this educational activity. 

Once you're logged in, please select the "REGISTER" tab to process your payment and complete your registration.

Once you register for the course, you will have 180 days (approximately 6 months) from the date of enrollment to complete the course. The exact date that your access expires will be indicated within the Course Summary box on this webpage.


Target Audience

Healthcare providers. 


Lessons for Optimizing Treatment (PILOT) is a national education initiative designed to provide physicians with a comprehensive continuing medical education activity that focuses on the early and accurate diagnosis of IPF while also addressing critical issues related to optimizing disease intervention and management. PILOT has attained a level of recognition and credibility across practitioner and patient communities that place it as one of the primary sources for timely and innovative education on IPF. In the 9 years since its launch, PILOT has had over 12 million hits to its Web site. In 2014, this initiative concluded with 70 live meetings and online activities that will be housed at


  • Evaluate clinical trial data on available and emerging treatments for Idiopathic Pulmonary Fibrosis (IPF) and potential application to practice
  • Explain the impact and treatment of common comorbidities of IPF
  • Identify opportunities for referral as part of the multidisciplinary IPF management plan



Mary Beth Scholand, MD is an assistant professor in Pulmonary Medicine from The University of Utah. Her research and clinical interest is Interstitial Lung Disease. This interest encompasses Idiopathic Pulmonary Fibrosis, Autoimmune Lung Diseases and Sarcoidosis. She is the Director of the Interstitial Lung Disease Clinic. She runs clinical trials focused on a cure for Idiopathic Pulmonary Fibrosis. In addition, her research focuses on phenotypic factors and genetic factors associated with Chronic Obstructive Pulmonary Diseases and Interstitial Lung Diseases.

Full biography. 

Needs Assessment Sources

  • Douglas WW, et al. Am J Respir Crit Care Med. 2000;161(4 Pt 1):1172-1178. 
  • Flaherty KR, et al. Eur Respir J. 2002;19:275-283.
  • Hubbard RB, et al. Am J Respir Crit Care Med. 2008;178:1257-1261.
  • IPF Clinical Research Network, et al. N Engl J Med. 2012;366:1968-1977. 
  • Lancaster LH, et al. Chest. 2009;136:772-778.
  • Lee JS, et al. Am J Respir Crit Care Med. 2011;184(12):1390-1394.
  • Lettieri CJ, et al. Chest .2006. 129:746-752.
  • Katz PO, et al. Am J Gastroenterol. 2013;108(3):308-328. 
  • King TE, et al. N Engl J Med. 2014;370(22):2083-2092.
  • Martinez FJ, et al. N Engl J Med. 2014;370(22):2093-2101.
  • Nagai S, et al. Sarcoidosis Vasc Diffuse Lung Dis. 1999;16(2):209-214.
  • Nathan SD, et al. Chest. 2011;140(1):221-229.
  • Nathan SD, et al. Respir Med. 2010:104:1035-1041.
  • Olson AL. Am J Respir Crit Care Med. 2007;176(3):277-284.
  • Raghu G, et al, and the ATS/ERS/JRS/ALAT Committee on IPF. Am J Respir Crit Care Med. 2011;183:788-824 
  • Raghu G, et al. Lancet Respir Med. 2014;2(7):566-572. 
  • Raghu G, et al; ATS, ERS, JRS, and ALAT. Am J Respir Crit Care Med. 2015;192(2):e3-e19.
  • Raghu G, et al. Am J Respir Crit Care Med. 2011;183(6):788-824. 
  • Richeldi L, et al. N Engl J Med. 2014;370(22):2071-2082.
  • Travis WD, et al, and the ATS/ERS Committee on IIPs. Am J Respir Crit Care Med. 2013;188(6):733-748. 
  • Washko GR, et al; Lung volumes and emphysema in smokers with interstitial lung abnormalities. N Engl J Med. 2011 Mar 10;364(10):897-906. doi: 10.1056/NEJMoa1007285
  • Weill D, et al. J Heart Lung Transplant. 2015;34(1):1-15.

    Copyright: All rights reserved. By viewing this activity, participants agree to abide by copyright and trademark laws, intellectual property rights, and all other applicable laws of the United States of America. No part of the syllabus may be used or reproduced in any manner whatsoever without written permission, except in the case of brief quotations embodied in articles or reviews.

    Internet CME Policy: The Office of Continuing Medical Education (CME) at Des Moines University (DMU) is committed to protecting the privacy of its customers. DMU CME maintains its Internet site as an information resource and service for health professionals. DMU CME will keep your personal and credit information confidential when you participate in an Internet based program. Your information will never be given to anyone outside of the DMU CME program. DMU CME collects only the information necessary to provide you with the services that you request.

    Course summary
    Available credit: 
    • 0.75 AMA PRA Category 1 Credits
    • 0.50 AOA Category 2­B
    • 0.75 CE Contact Hour(s)
    Course opens: 
    Course expires: 

    Continuing Education Credit

    • MD: This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Iowa Medical Society (IMS). Des Moines University (DMU) is accredited by the IMS to provide continuing medical education for physicians. DMU designates this enduring materials activity for a maximum of 0.75 AMA PRA Category 1 Credit(s)™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.
    • DO: Des Moines University is accredited by the American Osteopathic Association (AOA) and approves this enduring materials activity for 0.5 AOA Category 2-B credit(s).
    • Other: This enduring materials activity is designated for 0.75 AMA PRA Category 1 Credit(s)™.

    Educational Grant

    This CME activity is sponsored by The France Foundation.

    Available Credit

    • 0.75 AMA PRA Category 1 Credits
    • 0.50 AOA Category 2­B
    • 0.75 CE Contact Hour(s)


    Please login or Create an Account to take this course.